More recent data from melanoma mouse models have demonstrated that ablative RT reduces tumor burden in a CD8+ T-cell-dependent manner and increases priming of tumor antigen-specific T cells at tumor-draining lymph nodes (111). The gene discussed is CD8A; the disease is neoplasm.